CN1178679A - Chinese drug capsule for curing tetanic spondylitis and lumber vertebra hypertrophic hyperosteogeny - Google Patents
Chinese drug capsule for curing tetanic spondylitis and lumber vertebra hypertrophic hyperosteogeny Download PDFInfo
- Publication number
- CN1178679A CN1178679A CN 96119456 CN96119456A CN1178679A CN 1178679 A CN1178679 A CN 1178679A CN 96119456 CN96119456 CN 96119456 CN 96119456 A CN96119456 A CN 96119456A CN 1178679 A CN1178679 A CN 1178679A
- Authority
- CN
- China
- Prior art keywords
- radix
- rhizoma
- parts
- hyperosteogeny
- spondylitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The Chinese drug capsule is compounded with Caulis Sinomenii, prepared Radix aconiti, reticulate millettia, Cortex Erythrnae, Astragalus membranaceus and other 16 kinds of Chinese medicinal materials. It has fast and high cure effect on tetanic spondylitis and hypertrophic hyperosteogeny of cervical vertebra, thoracic vertabra and lumber vertebra without toxic side effect. It is widely used in curing bone and joint diseases caused by arthralgia arthralgia due to wind, cold and wetness evil.
Description
The present invention relates to a kind of pharmaceutical product that is shaped as feature with specific physical, particularly treat the Chinese medicinal capsule of ankylosing spondylitis, neck, breast, hyperosteogeny bone matrix hyperplasia, be the patient's of the sclerotin that causes because of anemofrigid-damp arthralgia of treatment and arthropathy choice drug, also effective to rheumatism, rheumatoid.
Ankylosing spondylitis, neck, breast, the hyperosteogeny bone matrix hyperplasia is a big illness that threatens human health, become one of important topic that medical circle research captures, people suffer from above-mentioned disease, not only suffer ailing the torment, obstinate, and have but cause lifelong maimed person, so so, be because the emphasis for the treatment of above-mentioned disease is at treatment rheumatism in the past, medication on the rheumatoid, and often ignored at benefiting qi and nourishing blood, strengthening the body resistance, the medication of human body immunity improving power aspect, it is long to cause showing clinically its course of treatment, the side effect of damage Liver and kidney is obvious, and the little situation of proving effective.
The object of the present invention is to provide that a kind of preparation technology is simple, cost is low, to indication short treating period instant effect, cure rate height, cure the Chinese medicinal capsule that is difficult for recurrence, the treatment ankylosing spondylitis that has no side effect, neck, breast, hyperosteogeny bone matrix hyperplasia.
Composition of the present invention and ratio of weight and number are as follows:
Caulis Sinomenii: Radix Aconiti Preparata: Caulis Spatholobi: Cortex erythrinae: Cornu Cervi Degelatinatum: the Radix Astragali: Herba Epimedii: Radix Codonopsis: the Rhizoma Atractylodis Macrocephalae: Radix Angelicae Sinensis: Rhizoma Chuanxiong: Rhizoma Cibotii: Olibanum: Myrrha: Radix Paeoniae Rubra: Rhizoma Cyperi: Rhizoma Et Radix Notopterygii: Radix Saposhnikoviae: Ramulus Cinnamomi: Herba Asari: the Radix Angelicae Dahuricae=, (4-6):, (4-6):, (4-6):, (6-9):, (11-14):, (14-16):, (8-12):, (6-9):, (6-9):, (4-6):, (4-6):, (6-9):, (4-6):, (4-6):, (4-6):, (4-6):, (4-6):, (4-6):, (4-6): 1:, (4-6).
Clinical practice by for many years and studies show that, rheumatism, rheumatoid just cause the risk factor of ankylosing spondylitis, neck, breast, hyperosteogeny bone matrix hyperplasia, and morbific main cause is because of its body void usually, body resistance against diseases is low, the gas that battalion defends is uncomfortable, interspaces of skin and muscles being loose, and the heresy that wind and cold is wet is taken advantage of a weak point, due to the infringement meridians, multiple abscess joint.Such as women puerperal, prolonged illness, wound, often catch a cold and personnel such as autoimmune insufficiency easily suffer from described disease.Based on above-mentioned cognition, then obstructed according to pain, general rule not bitterly, control wind and control blood earlier, the blood sector-style is from going out, cold then heat, wet then profit, harmonizing yingfen and weifen, the theory of Chinese medical science of strengthening the body resistance, dialectical executing controlled, and starts with from human body integral and nourishes blood and seek, expelling wind and removing dampness, the detumescence eliminating impediment, promoting the circulation of QI to relieve pain, strengthening the body resistance is realized the purpose for the treatment of both the principal and secondary aspects of a disease.Thereby on medication and compatibility relationship, demonstrate fully above-mentioned Therapeutic Principle, and reuse product unconventional escalated dose on its consumption of tonification, make its effect rapidly lasting, can QI invigorating and body resistance strengthening consolidate such as the adding of Cornu Cervi Degelatinatum, Herba Epimedii, the Radix Astragali, Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae; Adding again can expelling wind and removing dampness, the Caulis Sinomenii of dredge the meridian passage, Radix Aconiti Preparata, Caulis Spatholobi, Cortex erythrinae; The introducing of Radix Angelicae Sinensis, Rhizoma Chuanxiong, Rhizoma Cibotii, Olibanum, Myrrha, Radix Paeoniae Rubra, Rhizoma Cyperi can nourishing blood and promoting blood circulation, and being equipped with can harmonizing yingfen and weifen again, Rhizoma Et Radix Notopterygii, Radix Saposhnikoviae, Ramulus Cinnamomi, Herba Asari, the Radix Angelicae Dahuricae of detumescence eliminating impediment.It is scientific and reasonable through clinical further checking for the compatibility of above-mentioned kinds of traditional Chinese medicines, definite effect.
Content of the present invention is further described by embodiment:
Example 1, get 4 parts of Caulis Sinomeniis, 5 parts of Radix Aconiti Preparatas, 6 portions of Caulis Spatholobis, 7 parts of Cortex erythrinaes, 11 parts of Cornu Cervi Degelatinatums, 16 parts of Radixs Astragali, 10 parts of Herba Epimedii, 6 parts of Radix Codonopsis, 9 parts of Rhizoma Atractylodis Macrocephalaes, 5 parts of Radix Angelicae Sinensis, 4 parts of Rhizoma Chuanxiongs, 8 parts of Rhizoma Cibotii, 6 parts of Olibanums, 5 parts of Myrrhas, 4 parts of Radix Paeoniae Rubra, 6 portions of Rhizoma Cyperis, 5 portions of Rhizoma Et Radix Notopterygiis, 4 parts of Radix Saposhnikoviaes, 5 parts of Ramulus Cinnamomi, 1 part of Herba Asari and 6 parts of Radixs Angelicae Dahuricae, encapsulated through the Powdered medicament mixed of pulverize separately, after stirring.Every 0.25 gram.
Example 2, learn from else's experience be ground into 6 parts of pulverous Caulis Sinomeniis, 4 parts of Radix Aconiti Preparatas, 5 parts of Caulis Spatholobis, 6 parts of Cortex erythrinaes, 14 parts of Cornu Cervi Degelatinatums, 15 parts of the Radixs Astragali, 8 parts of Herba Epimedii, 7 parts of Radix Codonopsis, 6 parts of the Rhizoma Atractylodis Macrocephalaes, 6 parts of Radix Angelicae Sinensis, 5 parts of Rhizoma Chuanxiongs, 6 parts of Rhizoma Cibotii, 5 parts of Olibanums, 6 parts of Myrrhas, 5 parts of Radix Paeoniae Rubra, 5 parts of Rhizoma Cyperis, 4 parts of Rhizoma Et Radix Notopterygiis, 6 parts of Radix Saposhnikoviaes, 4 parts of Ramulus Cinnamomi, 1 part of Herba Asari and the Radix Angelicae Dahuricae be mixed for 4 parts stir encapsulated.Every 0.5 gram.
Example 3, learn from else's experience be ground into 5 parts of pulverous Caulis Sinomeniis, 6 parts of Radix Aconiti Preparatas, 4 parts of Caulis Spatholobis, 9 parts of Cortex erythrinaes, 12 parts of Cornu Cervi Degelatinatums, 14 parts of the Radixs Astragali, 12 parts of Herba Epimedii, 9 parts of Radix Codonopsis, 7 parts of the Rhizoma Atractylodis Macrocephalaes, 4 parts of Radix Angelicae Sinensis, 6 parts of Rhizoma Chuanxiongs, 9 parts of Rhizoma Cibotii, 4 parts of Olibanums, 4 parts of Myrrhas, 6 parts of Radix Paeoniae Rubra, 4 parts of Rhizoma Cyperis, 6 parts of Rhizoma Et Radix Notopterygiis, 5 parts of Radix Saposhnikoviaes, 6 parts of Ramulus Cinnamomi, 1 part of Herba Asari and the Radix Angelicae Dahuricae be mixed for 5 parts stir encapsulated.Every 0.25 gram.
Use obey time three times, each 4-6 grain, 30 days is a course of treatment, anemia of pregnant woman's forbidding.
The present invention compared with prior art since pathogenesis diagnosis accurately, scientific composition, medication be reasonable, Thereby clinical manifestation its treat both principal and secondary aspect of disease, can eliminate ailing the torment and can make again the sclerotin pine dredge the hypertrophy position Reposition, tetanic spondylitis are recovered slight motor function, its efficient reaching more than 98%, to indication Instant effect, short treating period, curative effect be lasting, cure the advantage that is difficult for recurrence, have no side effect, the while preparation technology Simply, cost is low, obviously reduce patient's financial burden, be beneficial to and apply.
Claims (2)
1. Chinese medicinal capsule for the treatment of ankylosing spondylitis, neck, breast, hyperosteogeny bone matrix hyperplasia is characterized in that forming with ratio of weight and number as follows:
Caulis Sinomenii: Radix Aconiti Preparata: Caulis Spatholobi: Cortex erythrinae: Cornu Cervi Degelatinatum: the Radix Astragali: Herba Epimedii: Radix Codonopsis: the Rhizoma Atractylodis Macrocephalae: Radix Angelicae Sinensis: Rhizoma Chuanxiong: Rhizoma Cibotii: Olibanum: Myrrha: Radix Paeoniae Rubra: Rhizoma Cyperi: Rhizoma Et Radix Notopterygii: Radix Saposhnikoviae: Ramulus Cinnamomi: Herba Asari: the Radix Angelicae Dahuricae=, (4-6):, (4-6):, (4-6):, (6-9):, (11-14):, (14-16):, (8-12):, (6-9):, (6-9):, (4-6):, (4-6):, (6-9):, (4-6):, (4-6):, (4-6):, (4-6):, (4-6):, (4-6):, (4-6): 1:, (4-6).
2. Chinese medicinal capsule according to claim 1 is characterized in that forming with ratio of weight and number as follows:
Caulis Sinomenii: Radix Aconiti Preparata: Caulis Spatholobi: Cortex erythrinae: Cornu Cervi Degelatinatum: the Radix Astragali: Herba Epimedii: Radix Codonopsis: the Rhizoma Atractylodis Macrocephalae: Radix Angelicae Sinensis: Rhizoma Chuanxiong: Rhizoma Cibotii: Olibanum: Myrrha: Radix Paeoniae Rubra: Rhizoma Cyperi: Rhizoma Et Radix Notopterygii: Radix Saposhnikoviae: Ramulus Cinnamomi: Herba Asari: the Radix Angelicae Dahuricae=5: 6: 4: 9: 12: 14: 12: 9: 7: 4: 6: 9: 4: 4: 6: 4: 6: 5: 6: 1: 5.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 96119456 CN1178679A (en) | 1996-10-07 | 1996-10-07 | Chinese drug capsule for curing tetanic spondylitis and lumber vertebra hypertrophic hyperosteogeny |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 96119456 CN1178679A (en) | 1996-10-07 | 1996-10-07 | Chinese drug capsule for curing tetanic spondylitis and lumber vertebra hypertrophic hyperosteogeny |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1178679A true CN1178679A (en) | 1998-04-15 |
Family
ID=5125712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 96119456 Pending CN1178679A (en) | 1996-10-07 | 1996-10-07 | Chinese drug capsule for curing tetanic spondylitis and lumber vertebra hypertrophic hyperosteogeny |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1178679A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100361680C (en) * | 2005-09-12 | 2008-01-16 | 董伟胜 | Medicine for treating backbone disease |
CN102018792A (en) * | 2010-11-19 | 2011-04-20 | 王丽华 | Traditional Chinese medicine for treating ankylosing spondylitis |
CN104997897A (en) * | 2015-07-31 | 2015-10-28 | 成都市飞龙水处理技术研究所 | Decoction drug for treating rheumatoid lumbar hypertrophy and preparation method thereof |
-
1996
- 1996-10-07 CN CN 96119456 patent/CN1178679A/en active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100361680C (en) * | 2005-09-12 | 2008-01-16 | 董伟胜 | Medicine for treating backbone disease |
CN102018792A (en) * | 2010-11-19 | 2011-04-20 | 王丽华 | Traditional Chinese medicine for treating ankylosing spondylitis |
CN102018792B (en) * | 2010-11-19 | 2012-09-12 | 王丽华 | Traditional Chinese medicine for treating ankylosing spondylitis |
CN104997897A (en) * | 2015-07-31 | 2015-10-28 | 成都市飞龙水处理技术研究所 | Decoction drug for treating rheumatoid lumbar hypertrophy and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100361704C (en) | Medicated wine for treating rheumatosis and osteoarthropathy | |
CN102091295B (en) | Chinese medicinal composition for treating femoral head necrosis and preparation method thereof | |
CN1099983A (en) | Medicine for treating rheumatoid or rheumatic arthritis and hyperosteogeny, and method for preparing same | |
CN101152397A (en) | Traditional Chinese medicine for treating delayed fracture healing | |
CN1237427A (en) | Adhesive plaster for curing prolapse of lumbar intervertebral disk | |
CN1332702C (en) | Medicine for treating psoriasis | |
CN101590104A (en) | A kind of Chinese medicine for the treatment of obstructive angiitis | |
CN101690768B (en) | Vein and artery relieving pills for impediment of sinew | |
CN1317021C (en) | Chinese medicinal formulation for stopping pain for removing Bi | |
CN1546066A (en) | Gastrointestinal ulcer treating Chinese traditional medicine | |
CN101130052A (en) | Traditional Chinese medicine for treating postpartum arthralgia | |
CN101167932A (en) | Traditional Chinese medicine for treating chronic hepatitis B | |
CN1178679A (en) | Chinese drug capsule for curing tetanic spondylitis and lumber vertebra hypertrophic hyperosteogeny | |
CN101129893A (en) | Traditional Chinese medicine for treating cervical spondylosis with diarrhea | |
CN103721082A (en) | Traditional Chinese medicinal composition for treating scapulohumeral periarthritis | |
CN1067571C (en) | Chinese medicine capsule for treating lumbar and cervical protrusion | |
CN101940726B (en) | Medicament for treating tourette syndrome | |
CN1217202A (en) | Medicine for treating rheumatic diseases | |
CN101837111A (en) | Medicament for curing proliferation of mammary glands and preparation method thereof | |
CN101284087B (en) | Medicinal composition for curing lumbar disease | |
CN101152300A (en) | Traditional Chinese medicine for treating stasis type intestinal obstruction | |
CN1219402A (en) | Chinese medicinal pill for curing rheumatism and rheumatoid disease and its preparation method | |
CN1132096A (en) | Chinese drug for treatment of hemiplegia | |
CN101129709A (en) | Traditional Chinese medicine for treating old fracture and lumbago of old people | |
CN1113667C (en) | Medicine for treating rheumatic and rheumatoid diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C01 | Deemed withdrawal of patent application (patent law 1993) | ||
WD01 | Invention patent application deemed withdrawn after publication |